Overview

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.

Phase:

Phase 3

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Patient-Centered Outcomes Research Institute

Treatments:

Azithromycin